Management of Refractory/Aggressive Pituitary Adenomas Review of Current Treatment Options by Dai, Congxin et al.
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter
Management of Refractory/
Aggressive Pituitary Adenomas
Review of Current Treatment
Options
Congxin Dai, Xiaohai Liu, Sihai Ma, Ming Feng, Xinjie Bao,
Kan Deng, Yong Yao, Renzhi Wang, DX. Feng, E. Fonkem,
Frank Y. Shan and Jason H. Huang
Abstract
Tumors of central nervous system (CNS) account for a small portion of tumors
of human body, which includes tumors occurring in the parenchyma of brain and
spinal cord as well as their coverings. This chapter covers some new development in
some major brain tumors in both pediatric and adult populations, as well as some
uncommon but diagnostic and management challenging tumors.
Keywords: refractory pituitary adenoma, macroadenoma and microadenoma,
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1. Introduction
The anterior pituitary gland (adenohypophysis) is an important organ for
human development and physiological functions (so called “Master Gland”), which
comprises several different cell types, responsible for the synthesis and secretion of
a specific hormone or group of specific hormones (plurihormonal), such as growth
hormone (GH), adrenocorticotrophic hormone (ACTH), and prolactin (PRL). Each
of these cell types may give rise to a discrete pituitary adenoma (PA) subtype that is
either hormonal active (functional) or inactive (nonfunctional).
As one of the most common pituitary neuroendocrine tumors, pituitary adeno-
mas (PAs) constitute the overwhelming majority of tumors arising in the pituitary
gland and account for 10–15% intracranial neoplasms. Incidental microadenoma
(smaller than 10 mm in diameter) may occur in up to 27% of pituitary glands
examined at autopsy, and up to one-fifth of the human population has pituitary
abnormalities on magnetic resonance imaging (MRI).
Majority of PAs are benign and slow growing; however, up to 10% of PAs are
aggressive with invasive growth and can exhibit clinical abnormal behavior with
high rates of recurrences [1]. Based on the recent WHO classification in 2017, a
more detailed tumor classification by immunohistochemical stain (IHC) was pro-
posed, which identifies a subset of PAs with aggressive clinical behavior character-
ized by clinical recurrence, which includes PAs with elevated Ki-67 proliferation
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index, sparsely granulated somatotroph PAs, Lactotroph PAs in men, silent
corticotroph PAs, Crooke cell PAs, and plurihormonal PAs with PIT-1 positivity.
PIT-1 is one of the pituitary transcription factors, sometimes to be used to clarify
the PAs’ tumor linages.
Clinically, a subset of aggressive PAs characterized with high Ki-67 index, rapid
growth, frequent recurrence, and resistant to conventional treatments is defined as
refractory PAs [2]. These refractory PAs often have a very poor prognosis and even
with an occasionally fatal outcome; however, there is no general agreement about
how to manage the patient with refractory PAs. For neurosurgeons and clinicians, it
is difficult to optimally choose the therapeutic options in treatment of refractory
PAs in order to improve the prognoses of these patients; it is very important and
necessary to review the emerging treatments for refractory PAs. This chapter is
going to review some current treatment options for those refractory PAs.
2. Management of refractory PAs by surgical treatment
Typically, multimodal approaches are required for managing refractory PAs.
Except prolactin-secreting adenomas (prolactinomas), which should be first treated
with dopamine agonists (DAs), the primary treatment option is usually surgery,
even surgery is usually unable to cure or control the refractory PAs [3]. However,
the therapeutic goals of surgery are maximum reduction of tumor mass, decom-
pression of visual pathways, best possible reduction of hormonal oversecretion,
amelioration of clinical symptoms, and minimization of complications [4].
Most of the refractory PAs are largely invasive, infiltrating adjacent tissues;
repeated surgery seldom achieves complete tumor excision. However, surgical
resection is still necessary to relieve compressive symptoms [5].
Repeated trans-sphenoidal surgery is generally more difficult to perform than
the initial operation due to the increased risk of morbidity and mortality. The
comparison of microscopic craniectomy and endoscopic approach for recurrent or
residual pituitary adenomas remains controversial.
Heringer performed a meta-analysis to evaluate effect of repeated trans-
sphenoidal surgery in recurrent or residual pituitary adenomas and found that half of
secreting tumors and more than half of nonfunctional pituitary adenomas (NFPAs)
could achieve remission after surgery, and there is no difference between endoscopic
and microscopic approach [6]. However, Esquenazi and his colleagues performed
another meta-analysis to compare the effects of endoscopic and microscopic trans-
sphenoidal surgery on recurrent and/or residual pituitary adenomas and found that
endoscopic surgery led to modest increases in resection rates on residual or recurrent
adenomas [7]. Do et al. [8] retrospectively analyzed 61 patients with recurrent or
residual pituitary adenomas who underwent endoscopic endonasal surgery and found
that the gross total resection was achieved in 31 patients (51.7%), indicating that
endoscopic endonasal approach is a safe and effective option for recurrent pituitary
adenomas. The results from another meta-analysis performed by Li also indicated that
the endoscopic surgery is related to higher gross tumor removal and lower incidence
of complications in patients with PA [9]. Almeida accessed the outcomes of
reoperation for patients with residual or recurrent growth hormone-secreting PA
from authors’ institution, and no statistically significant difference was found in
disease control rates between the reoperation and first-time neurosurgery. They
further systematically reviewed 161 reoperations and 2189 first-time surgery cases
retrieved from 29 papers and found that reoperation and first-time surgery had
similar control rates for microadenomas, but the reoperation was related to substan-
tially lower control rates for macroadenomas (27.5%) and tumors invading the
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cavernous sinus (14.7%) [10]. In 2016, a systematic review and evidence-based
guideline for the residual or recurrent NFPAs was produced by Congress of Neuro-
logical Surgeons, and the repeat resection is recommended as level III recommenda-
tions for the treatment of symptomatic recurrent or residual NFPAs [11].
Based on the previous studies and our experience, endoscopic surgery is better
than the microscopic surgery for recurrent pituitary adenomas; however, these
findings are needed to be verified by the large-scale prospective randomized con-
trolled trials. Therefore, maximum tumor resection, meanwhile preserving nerve
function is the goal to achieve local control and decompress vital structures for
those refractory PAs with compressive symptoms.
3. Radiation therapy
Despite the success of trans-sphenoidal surgery or maximum tumor resection, most
refractory PAswill regrow or recur; therefore, other therapeutic approaches are usually
necessary. If surgical and/medical therapy failed to control the tumor growth, radiation
therapy (RT) is currently the next treatment option [1]. There are several RT options
for patients with refractory PAs. Fractionated external beam radiation therapy (EBRT)
has been used for several decades and has shown good clinical safety and efficacy [12].
Stereotactic radiosurgery (SRS) is the delivery of a high single dose of radiation under
conditions of accurate positioning. Recently, SRS has been gaining popularity due to
the minimizing exposure of normal brain tissue to radiation. SRS has been preferred
over fractionated photon beam because of the convenience of single day therapy and
the potential for the faster effect on tumor [13]. A variety of SRS including Gamma
Knife, CyberKnife, and proton-beam RT are available to deliver stereotactic RT. How-
ever, some refractory PAs are not candidates for stereotactic RT because of the tumor
size (>3 cm), or tumor location near the optic apparatus and brainstem (<5 mm) [14].
Risks associated with RT include hypopituitarism, optic neuropathy, and other cranial
neuropathies, which should be concerned and avoided [12].
Comparing EBRT and SRS may help to guide decision making for patients with
residual or recurrent pituitary tumors. Kong et al. [15] compared the efficacy and
safety of SRS and EBRT for the treatment of 125 patients with PAs. Although no
significant difference was found in either biochemical remission or tumor growth
control, the time to biochemical remission after SRS was much shorter than EBRT
(26 months vs. 63 months).
To better understand the effects of SRS for Cushing disease (CD), Mehta et al.
[16] performed an international, multicenter, retrospective cohort analysis, 278
patients with CD received SRS was retrospective cohort analyzed, and found that
the overall rate of durable control of hypercortisolism was 64% for 10 years, and the
adverse radiation effects included hypopituitarism (25%) and cranial neuropathy
(3%) were observed.
Both conventional radiotherapy and stereotactic RT have shown a good
tumoristatic effect on typical PAs; however, theymay be largely ineffective and rarely
maintain a long-term remission in refractory PAs. As a matter of fact, one of the
aggressive PAs with high recurrent potential, silent corticotroph PAs, is with high
sensitivity to radiation, so RT can be a good option for patients with those kind of PAs.
4. Medical therapy
Medical therapy plays an increasingly important role in the management of PAs.
Temozolomide (TMZ), an orally administered alkylating chemotherapy, is
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recommended as the first-line chemotherapy for aggressive pituitary tumors and
pituitary carcinomas after the failure of standard therapies by the European Society
of Endocrinology [17]. TMZ is considered the standard treatment in the manage-
ment of gliomas. Since 2006, the first successful treatment of PA with TMZ was
reported [18, 19], and TMZ treatment has also been widely used for patients with
refractory PAs and carcinomas [20]. However, only about 50% of pituitary tumors
are sensitive to TMZ treatment, and most of the refractory PAs failed to respond to
TMZ and even acquired TMZ resistance after the effective response to TMZ [21].
Therefore, it is important to enhance the efficacy of TMZ and overcome the resis-
tance of TMZ. Some molecular status of pituitary tumors, such as O6—
methylguanine-DNA-methyltransferase MGMT and MSH6, has been associated
with temozolomide response [22]. It is reported that the PI3K/AKT/mTOR signaling
pathway is upregulated in pituitary tumors, and the inhibition of this pathway may
enhance the TMZ-mediated cytotoxicity [23].
Epidermal growth factor receptor (EGFR) is a cell growth factor, which regu-
lates cell proliferation and hormone production in pituitary tumors [24]. EGFR is
overexpressed in prolactinoma and ACTH-secreting pituitary adenomas, which
may offer a potential therapeutic target for refractory pituitary tumors [25, 26]. As
an EGFR inhibitor, gefitinib has shown antiproliferative and apoptotic effects in
corticotroph tumor cell in vitro [25]. Lapatinib, a dual HER2/EGFR inhibitor, was
shown to both suppressed PRL mRNA expression and secretion more than gefitinib
in animal model of prolactinomas [27].
Although further clinical trials are needed, preclinical data suggest that the
EGFR pathway may be an effective therapeutic targeting for patients with refrac-
tory pituitary tumors.
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor in
pituitary tumors. The previous studies indicated that angiogenesis is associated with
adenoma development, local invasion, and recurrences [28–30]. Several researches
reported that angiogenesis decrease tumor sizes in human and experimental pitui-
tary tumors [31–33]. Ortiz has reported the first case of a bevacizumab-treated
pituitary carcinoma with long-term stabilization of disease in 2012 [34]. Touma also
presented one case of pituitary carcinoma treated successfully with concurrent
chemoradiation therapy and bevacizumab with a long-term follow up [35]. How-
ever, the role of anti-VEGF therapy in pituitary tumors is still controversial due to
the lack of large-scale clinical trial.
Phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin
(mTOR) cascades is key signaling pathways in tumorigenesis of pituitary adenoma
[36]. The previous studies reported that the PI3K/AKT/mTOR pathway is
upregulated and overactivated in pituitary adenomas, implicating an important role
in tumor formation and progression of pituitary adenoma [37–39]. Inhibition of the
PI3K/mTOR signaling pathway not only displays antitumor efficacy against pitui-
tary tumor [40, 41] but also sensitizes pituitary adenoma cells to radiotherapy and
chemotherapy [23, 42]. Donovan reported one patient with pituitary carcinoma,
which is refractory to multiple surgery, radiation, and chemotherapy, after the
treatment with mTOR inhibitor (everolimus) and radiation, and the clinical
improvement and stability >6 months were achieved [43].
As a promising therapeutic approach, cancer immunotherapy has been
attracting more and more attention recently. To date, immunotherapy has been
applied for the treatment of many tumors including glioma, lung cancer, mela-
noma, prostate cancer, and B cell lymphoma [44]. In 2007, Hazrati and his col-
leagues have reported one case of a prolactinoma treated successfully with
immunotherapy for the first time [45]. Lu has reported that CD68+ macrophage
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infiltration is associated with the pituitary adenoma size and invasiveness, indicat-
ing that immunotherapy may be useful to restrict the tumor enlargement and
invasiveness [46]. Blocking the interaction between the programmed cell death
(PD-1) protein and one of its ligands, programmed death ligand 1 (PD-L1) is one
of the novel strategies for cancer immunotherapy. The expression of PD-L1 is
positively correlated with improved responses to anti-PD-1/PD-L1 blockade in
many cancers [47]. Mei reported that the expression of (PD-L1) is significantly
higher in human functioning adenomas compared to nonfunctioning adenomas,
suggesting the existence of an immune response to pituitary tumors [48]. There-
fore, these researches raise the possibility of considering immunotherapy for the
refractory PAs.
5. Conclusion
Although various treatment options are available to manage these refractory
pituitary tumors, the efficacy is limited. Therefore, the new therapeutic approaches
and such randomized clinical trials are needed. It is hoped that further research may
clarify the tumorigenesis and pathogenesis of refractory PAs, and additional alter-
native treatments may be developed for these tumors in the near future.
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